Intensity Therapeutics Earnings Reports

Intensity Therapeutics significantly reduced its net loss in Q2 2025 to $2.5 million from $5.0 million in the prior year, primarily due to decreased research and development expenses. The company also successfully raised over $11 million, extending its cash runway into the second half of 2026.

Intensity Therapeutics reported a lower net loss in Q1 2025 compared to the same period last year, primarily due to reduced research and development and general and administrative expenses. The company paused new site activations and patient enrollments for the INVINCIBLE-3 study due to funding constraints, prioritizing funding for the INVINCIBLE-4 study.

Intensity Therapeutics reported a net loss of $16.3 million for the year ended December 31, 2024, an increase from a net loss of $10.5 million in the prior year. Research and development expenses significantly increased due to the progression of the INVINCIBLE-3 and INVINCIBLE-4 studies, while cash and cash equivalents stood at $2.6 million.

Intensity Therapeutics reported a net loss of $3.5 million for the third quarter of 2024. The company's cash and cash equivalents totaled $2.8 million as of September 30, 2024, expected to fund operations into the first quarter of 2025. The first patient was dosed in randomized, Phase 2 study in presurgical triple negative breast cancer

Intensity Therapeutics reported a net loss of $5.0 million for the second quarter of 2024, compared to a net loss of $3.7 million for the same period in 2023. As of June 30, 2024, cash, cash equivalents and marketable debt securities totaled $6.3 million, which is expected to fund operations into the first quarter of 2025. The company dosed its first patient in a Phase 3 study in metastatic soft tissue sarcoma and entered into a collaboration agreement with SAKK for a Phase 2 study in early-stage breast cancer.

Intensity Therapeutics reported a net loss of $4.6 million for the first quarter of 2024, with research and development expenses increasing to $2.8 million and general and administrative expenses rising to $1.9 million. As of March 31, 2024, cash, cash equivalents, and marketable debt securities totaled $10.5 million, expected to fund operations through the end of the first quarter of 2025.

Intensity Therapeutics reported its full year 2023 financial results, highlighting the advancement of its lead drug candidate, INT230-6, into late-stage clinical programs and a year-end cash position of $14.8 million expected to fund operations through Q1 2025.